{
    "pmcid": "9869787",
    "qa_pairs": {
        "What limitation did the study face regarding the neutralization assays?": [
            "The study did not perform live virus neutralization assays due to biosafety constraints",
            "The study did not evaluate the nanobodies against other SARS-CoV-2 variants",
            "The study did not use prokaryotic expression systems for nanobody production",
            "The study did not perform peptide-based ELISA for epitope mapping"
        ],
        "What method was used to assess the binding affinity and neutralizing activity of the nanobodies against SARS-CoV-2?": [
            "Surface plasmon resonance (SPR) assays and pseudovirus neutralization tests",
            "Cryo-electron microscopy and live virus neutralization assays",
            "X-ray diffraction and peptide-based ELISA",
            "Prokaryotic expression systems and multimerization studies"
        ],
        "What was the purpose of engineering a multivalent format for the nanobodies?": [
            "To increase the thermal stability and neutralizing activity",
            "To reduce the size and improve the production yield",
            "To enhance the specificity for the wild-type RBD",
            "To decrease the binding affinity and increase the IC50 value"
        ],
        "What was the source of the protein nanoplatform used for multivalency in the study?": [
            "Lumazine synthase (AaLS) from Aquifex aeolicus",
            "Receptor-binding domain (RBD) from SARS-CoV-2",
            "Spike protein from the Omicron variant",
            "Monoclonal antibodies from camelids"
        ],
        "Which nanobody showed the best neutralizing activity against the Omicron variant?": [
            "B-B2",
            "LS-B-B2",
            "AaLS",
            "RBD-1"
        ]
    }
}